Orilanolimab - CISMeF

Preferred Label : Orilanolimab;

NCIt synonyms : Immunoglobulin G4, Anti-(Human FcRn Receptor) (Humanized Monoclonal SYNT001 gamma4-Chain), Disulfide with Humanized Monoclonal SYNT001 kappa-Chain, Dimer;

NCIt related terms : Anti-FcRn Monoclonal Antibody SYNT001;

NCIt definition : A monoclonal antibody that targets the neonatal crystallizable fragment receptor (FcRn), with potential immunomodulating activity. Upon administration, orilanolimab targets and binds to FcRn at the immunoglobulin G (IgG) binding site, thereby preventing the interaction between FcRn and the serum protein IgG. By preventing FcRn/IgG binding, SYNT001 blocks the FcRn-mediated rescue of IgG, enables IgG degradation and prevents IgG-mediated inflammation. IgG plays a key role in many autoimmune diseases and is an important factor in inflammatory processes.;

UNII : 1LTT6HMX9N;

CAS number : 2066544-85-0;

Molecule name : SYNT 001; SYNT-001;

NCI Metathesaurus CUI : CL526914;

Détails

Origin ID

C139561;

UMLS CUI

C5139911;

Currated CISMeF NLP mapping
- Orilanolimab [SMS substance]
- orilanolimab [MeSH Supplementary Concept]
- orilanolimab [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- orilanolimab [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients